months. The introduction of cyclophosphamide 50 mg daily, 9 months after presentation, initially in conjunction with further prednisolone (1 mg ⁄ kg), rendered the inhibitor transiently undetectable, with FVIII:C peaking at 40 il ⁄ dl. However, with reduction of the prednisolone dose, the inhibitor returned, and the FVIII:C fell. After 9 months of treatment with cyclophosphamide, it was discontinued because of lack of a sustained response.
Approximately 28 months after presentation, cyclosporin A (CyA) was introduced at 100 mg twice daily (3 mg ⁄ kg ⁄ d), initially with prednisolone (1 mg ⁄ kg). A target trough plasma CyA concentration of 200-250 mg ⁄ l was achieved over 3 months with a dose of 175 mg twice daily ( 5 mg ⁄ kg ⁄ d), during which time the prednisolone was discontinued. The inhibitor titre fell and was undetectable 3 months after the commencement of CyA. The FVIII:C rose to within the normal range following disappearance of the inhibitor (Fig 1) . After 14 months of therapy with CyA, and with FVIII:C levels remaining in the normal range, cyclosporine was reduced and stopped over a 4-month period. Ten months after cessation of all immunosuppressive therapy, the FVIII:C remains in the normal range with no detectable inhibitor.
Permanent eradication of inhibitor without the need for continued therapy is the ultimate aim of immunosuppressive treatment for acquired haemophilia. Initial reduction in inhibitor titre may be achieved with high-dose intravenous immunoglobulin and steroids; however, long-term clearance may not be achieved with this approach alone (Hay et al, 1996) . Further options include cytotoxic regimens or immunosuppressant agents such as cyclosporine. As no British Journal of Haematology, 2003 Haematology, , 122, 1024 Haematology, -1026 regime has been universally successful, and there have been no large immunomodulatory studies, no gold standard treatment has been established (Grunewald et al, 2001) . Cytotoxic therapy may be associated with neutropenic sepsis; such cases have been reported in the treatment of acquired haemophilia (Lian et al, 1989) . On the other hand CyA is well recognized as a precipitant of hypertension and renal impairment in addition to its anticipated immunosuppressive effects. The choice of treatment must then rest on the perceived risk of the options available.
This case demonstrates a lasting response attributed to CyA that was not achieved either by first-line therapy with steroid and intravenous immunoglobulin or by second-line therapy with cyclophosphamide. Although we cannot exclude spontaneous remission of the patient's FVIII inhibitor, the reduction in inhibitor titre commensurate with the introduction of CyA makes this unlikely. We conclude that CyA warrants consideration in patients refractory to firstline therapy for this rare but serious autoimmune disorder. 
MISCONCEPTIONS IN THALASSAEMIA DIAGNOSIS
A full blood count was requested on a 2-day-old Pakistani boy. The child had mild anaemia with thalassaemic indices, blood film showed anisocytosis, poikilocytosis, target cells and polychromasia (Table I) . High-performance liquid chromatography suggested a three alpha gene deletion with haemoglobin Barts 27AE7%, haemoglobin F 44AE6% and haemoglobin A 19%.
The mother's prenatal test results were normal (Table I ). The father's results suggested alpha-thalassaemia trait or silent beta-thalassaemia trait (Table I) . No other antenatal testing had been done as the fetus was not felt to be at risk of serious haemoglobinopathy.
Further questioning of the mother revealed she had had in vitro fertilization (IVF) using donated ova in another UK city. The donor, from Cyprus, had declared a family history of thalassaemia at the IVF clinic and therefore underwent screening. This was reported as showing possible iron deficiency, and a card was issued stating that she had no significant haemoglobinopathy. Antenatal haemoglobinopathy screening for the biological mother during a previous pregnancy had also been reported as normal. Two further separate screens over a period of years had failed to comment on the significance of thalassaemic indices in the presence of a normal haemoglobin and Hb A2.
DNA analysis showed the natural mother to have a Mediterranean a 0 deletion (-MED ⁄ aa), the father a 3AE7-kb a + -thalassaemia deletion (-a 3AE7 ⁄ aa) and the baby haemoglobin H disease (-a 3AE7 ⁄ -MED ). The donated ova from the same woman had also been used in other pregnancies, including a pregnancy using the donated ova and a sperm donor of Asian origin. This sperm donor had not had a haemoglobinopathy screen and had to be recalled.
This case highlights common problems in thalassaemia diagnosis, screening and reporting. Although guidelines for the laboratory diagnosis of haemoglobinopathies exist (British Committee for Standards in Haematology, General Haematology, 1998), there is currently no standardized reporting of results. The British Committee for Standards in Haematology (BCSH) guidelines state that screening is equally important in cases where pregnancy is the result of artificial insemination from a donor or in vitro fertilization, Mutations causing the a 0 -thalassaemia trait are found predominantly in south-east Asia, southern China (-SEA ⁄ aa, -FIL ⁄ aa and -THAI ⁄ aa) and the Mediterranean, particularly Cyprus, Turkey and Greece (-MED ⁄ aa). DNA analysis should be done in patients from these ethnic groups with a MCH < 25 pg and where b-and db-thalassaemia and haemoglobin Lepore have been excluded.
In this case, the ethnic origin of the natural mother was not taken into account and the a 0 -thalassaemia trait therefore not considered. In such cases, it is necessary to add a statement that the 'a-thalassaemia trait cannot be excluded' whether iron deficiency is present or not.
The National Health Service (NHS) plan is committed to a national, linked antenatal and neonatal screening programme for the haemoglobinopathies (NHS Plan, 2000) .
